145 related articles for article (PubMed ID: 8649832)
1. c-myc expression is activated by the immunoglobulin kappa-enhancers from a distance of at least 30 kb but not by elements located within 50 kb of the unaltered c-myc locus in vivo.
Mautner J; Behrends U; Hörtnagel K; Brielmeier M; Hammerschmidt W; Strobl L; Bornkamm GW; Polack A
Oncogene; 1996 Mar; 12(6):1299-307. PubMed ID: 8649832
[TBL] [Abstract][Full Text] [Related]
2. The intron enhancer of the immunoglobulin kappa gene activates c-myc but does not induce the Burkitt-specific promoter shift.
Polack A; Strobl L; Feederle R; Schweizer M; Koch E; Eick D; Wiegand H; Bornkamm GW
Oncogene; 1991 Nov; 6(11):2033-40. PubMed ID: 1945409
[TBL] [Abstract][Full Text] [Related]
3. The role of immunoglobulin kappa elements in c-myc activation.
Hörtnagel K; Mautner J; Strobl LJ; Wolf DA; Christoph B; Geltinger C; Polack A
Oncogene; 1995 Apr; 10(7):1393-401. PubMed ID: 7731690
[TBL] [Abstract][Full Text] [Related]
4. Variable IgH chain enhancer activity in Burkitt's lymphomas suggests an additional, direct mechanism of c-myc deregulation.
Jain VK; Judde JG; Max EE; Magrath IT
J Immunol; 1993 Jun; 150(12):5418-28. PubMed ID: 8515068
[TBL] [Abstract][Full Text] [Related]
5. Absence of a paused transcription complex from the c-myc P2 promoter of the translocation chromosome in Burkitt's lymphoma cells: implication for the c-myc P1/P2 promoter shift.
Strobl LJ; Kohlhuber F; Mautner J; Polack A; Eick D
Oncogene; 1993 Jun; 8(6):1437-47. PubMed ID: 8502472
[TBL] [Abstract][Full Text] [Related]
6. Deregulation of the proto-oncogene c-myc through t(8;22) translocation in Burkitt's lymphoma.
Gerbitz A; Mautner J; Geltinger C; Hörtnagel K; Christoph B; Asenbauer H; Klobeck G; Polack A; Bornkamm GW
Oncogene; 1999 Mar; 18(9):1745-53. PubMed ID: 10208435
[TBL] [Abstract][Full Text] [Related]
7. The in vivo binding site for oncoprotein c-Myc in the promoter for Epstein-Barr virus (EBV) encoding RNA (EBER) 1 suggests a specific role for EBV in lymphomagenesis.
Niller HH; Salamon D; Ilg K; Koroknai A; Banati F; Bauml G; Rucker O; Schwarzmann F; Wolf H; Minarovits J
Med Sci Monit; 2003 Jan; 9(1):HY1-9. PubMed ID: 12552250
[TBL] [Abstract][Full Text] [Related]
8. The Epstein-Barr virus BRLF1 gene product transactivates the murine and human c-myc promoters.
Gutsch DE; Marcu KB; Kenney SC
Cell Mol Biol (Noisy-le-grand); 1994 Sep; 40(6):747-60. PubMed ID: 7812182
[TBL] [Abstract][Full Text] [Related]
9. Topological organization of the MYC/IGK locus in Burkitt's lymphoma cells assessed by nuclear halo preparations.
Rätsch A; Joos S; Kioschis P; Lichter P
Exp Cell Res; 2002 Feb; 273(1):12-20. PubMed ID: 11795942
[TBL] [Abstract][Full Text] [Related]
10. Theophylline induced differentiation provides direct evidence for the deregulation of c-myc in Burkitt's lymphoma and suggests participation of immunoglobulin enhancer sequences.
Sandlund JT; Neckers LM; Schneller HE; Woodruff LS; Magrath IT
Cancer Res; 1993 Jan; 53(1):127-32. PubMed ID: 8416737
[TBL] [Abstract][Full Text] [Related]
11. An origin of DNA replication (oriP) in highly methylated episomal Epstein-Barr virus DNA localizes to a 4.5-kb unmethylated region.
Falk K; Ernberg I
Virology; 1993 Aug; 195(2):608-15. PubMed ID: 8393238
[TBL] [Abstract][Full Text] [Related]
12. Wild-type p53 induces apoptosis in a Burkitt lymphoma (BL) line that carries mutant p53.
Ramqvist T; Magnusson KP; Wang Y; Szekely L; Klein G; Wiman KG
Oncogene; 1993 Jun; 8(6):1495-500. PubMed ID: 8502475
[TBL] [Abstract][Full Text] [Related]
13. c-MYC impairs immunogenicity of human B cells.
Schlee M; Schuhmacher M; Hölzel M; Laux G; Bornkamm GW
Adv Cancer Res; 2007; 97():167-88. PubMed ID: 17419945
[TBL] [Abstract][Full Text] [Related]
14. ECA39 is regulated by c-Myc in human and by a Jun/Fos homolog, Gcn4, in yeast.
Ben-Yosef T; Yanuka O; Benvenisty N
Oncogene; 1996 Nov; 13(9):1859-66. PubMed ID: 8934531
[TBL] [Abstract][Full Text] [Related]
15. Regulatory elements in the immunoglobulin kappa locus induce c-myc activation and the promoter shift in Burkitt's lymphoma cells.
Polack A; Feederle R; Klobeck G; Hörtnagel K
EMBO J; 1993 Oct; 12(10):3913-20. PubMed ID: 8404859
[TBL] [Abstract][Full Text] [Related]
16. Suitability of Epstein-Barr virus-based episomal vectors for expression of cytokine genes in human lymphoma cells.
Mũcke S; Polack A; Pawlita M; Zehnpfennig D; Massoudi N; Bohlen H; Doerfler W; Bornkamm G; Diehl V; Wolf J
Gene Ther; 1997 Feb; 4(2):82-92. PubMed ID: 9081710
[TBL] [Abstract][Full Text] [Related]
17. IFN-gamma induces the kappa intron enhancer via an IFN-stimulated response element.
Damore MA; Omori SA; Wall R
J Immunol; 1996 Apr; 156(7):2451-7. PubMed ID: 8786304
[TBL] [Abstract][Full Text] [Related]
18. The immunoglobulin heavy-chain gene 3' enhancers deregulate bcl-2 promoter usage in t(14;18) lymphoma cells.
Duan H; Heckman CA; Boxer LM
Oncogene; 2007 Apr; 26(18):2635-41. PubMed ID: 17043638
[TBL] [Abstract][Full Text] [Related]
19. Activation of c-myc promoter P1 by immunoglobulin kappa gene enhancers in Burkitt lymphoma: functional characterization of the intron enhancer motifs kappaB, E box 1 and E box 2, and of the 3' enhancer motif PU.
Wittekindt NE; Hörtnagel K; Geltinger C; Polack A
Nucleic Acids Res; 2000 Feb; 28(3):800-8. PubMed ID: 10637333
[TBL] [Abstract][Full Text] [Related]
20. Retroviral enhancer insertion 5' of c-myc in two translocation-negative mouse plasmacytomas upregulates c-myc expression to different extents.
Shaughnessy JD; Owens JD; Wiener F; Hilbert DM; Huppi K; Potter M; Mushinski JF
Oncogene; 1993 Nov; 8(11):3111-21. PubMed ID: 8414513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
